L-Y Huang
Overview
Explore the profile of L-Y Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li S, Xie X, Liu D, Cheng G, Hu F, Zeng D, et al.
J Prev Alzheimers Dis
. 2024 May;
11(3):589-600.
PMID: 38706275
Background: Alzheimer's disease (AD), the most common type of irreversible dementia, is predicted to affect 152 million people by 2050. Evidence from large-scale preventive randomized controlled trials (RCTs) on modifiable...
2.
He Y, Zhou Q, Deng W, Huang L, Lu Y, Ruan Y, et al.
Eur Rev Med Pharmacol Sci
. 2023 Dec;
27(22):10926-10934.
PMID: 38039022
Objective: Brainstem tumors present a significant challenge in surgical treatment, and the prognostic factors in children are lacking. This study aimed to investigate clinical characteristics and prognostic factors of surgical...
3.
Fan H, Chen S, Li X, Huang L
Eur Rev Med Pharmacol Sci
. 2023 Apr;
27(7):2971-2979.
PMID: 37070898
Objective: This study aimed to investigate the efficacy of Traditional Chinese Herbs (TCH) combined with bioelectrical stimulation (BES) on patients with kidney deficiency and blood stasis type thin endometrium. Patients...
4.
Huang L, Chang H, Chang R, Tai H, Huang Y, Lee P
Eur Rev Med Pharmacol Sci
. 2022 Oct;
26(20):7632-7640.
PMID: 36314347
Objective: Non-squamous non-small cell lung cancer (NSCLC) is the first leading cause of cancer-related deaths in Taiwan. This study aimed at evaluating the effectiveness of first-line targeted therapy for advanced...
5.
Tsai H, Chang H, Chen C, Hsu W, Huang L, Lee P
Eur Rev Med Pharmacol Sci
. 2021 Dec;
25(23):7543-7552.
PMID: 34919256
Objective: We analyzed real-world data to elucidate the effects of anti-Hepatitis C virus (HCV) direct-acting antiviral (DAA) therapy on survival in patients with advanced hepatocellular carcinoma (HCC) and concomitant HCV...
6.
Hsieh S, Ho H, Tai H, Chien L, Chang H, Chang H, et al.
Eur Rev Med Pharmacol Sci
. 2021 Nov;
25(21):6548-6556.
PMID: 34787857
Objective: Immune checkpoint inhibitors (ICIs) are a major advance in cancer treatment, but their payment benefits are unclear, resulting in financial risk. In Taiwan, the National Health Insurance Administration (NHIA)...
7.
Lin C, Huang L, Wu K, Chan J, Wu K, Shyu H, et al.
QJM
. 2021 Sep;
114(12):910-911.
PMID: 34546343
No abstract available.
8.
Wang Y, Huang L, Chen Y, Chan J, Chiang W, Lin C, et al.
QJM
. 2021 Aug;
114(10):733-734.
PMID: 34432063
No abstract available.
9.
Wang R, Chiang W, Shyu H, Chen M, Lin C, Wu K, et al.
QJM
. 2021 Jul;
114(7):506-507.
PMID: 34247246
No abstract available.
10.
Huang L, Chen T, Yang M, Shau W, Su S, Lai M
Eur Rev Med Pharmacol Sci
. 2021 May;
25(9):3499-3506.
PMID: 34002824
Objective: Our understanding of therapeutic inertia in diabetes care is incomplete in terms of an assessment across a nationwide population. The key objectives of this investigation were to measure therapeutic...